Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TELOthis companyTelomir Pharmaceuticals, Inc. Common Stock	$0.70	-4.03×	7.12×	0×	-3.39×	-78.2%	0.0%	0.0%	0.0%	-176.1%	-165.0%	-8.8%	0.08×	0.65×	0×	5.14×	0.0%	2	107.7	1	C-
CVMCEL-SCI Corporation	$1.49	-1.47×	2.34×	0×	-1.71×	-84.4%	0.0%	0.0%	0.0%	-159.2%	-97.4%	-46.0%	0.59×	0.08×	-38.23×	2.26×	0.0%	2	-38.36	2	C
EQEquillium, Inc.	$1.59	-3.97×	4.98×	0×	-5.06×	-77.1%	0.0%	0.0%	0.0%	-78.3%	-83.3%	-16.0%	0.03×	1.33×	0×	10.32×	0.0%	1	14.51	2	C
INMBINmune Bio, Inc.	$1.14	-0.84×	1.76×	829.46×	-0.39×	-44.6%	100.0%	-61738.0%	-91866.0%	-195.3%	-125.7%	-57.0%	0.04×	0.52×	0×	3.55×	0.0%	1	-9.17	2	C+
IPSCCentury Therapeutics, Inc.	$1.74	-9.04×	0.54×	0.79×	19.64×	85.0%	88.0%	-13.8%	-8.8%	-6.0%	-7.2%	-121.6%	0.27×	-5.3×	0×	5.97×	0.0%	1	-1.94	2	C
KPTIKaryopharm Therapeutics Inc.	$0.04	-0.41×	-0.27×	0.55×	-1.69×	-58773.0%	95.9%	-62.1%	-134.2%	66.9%	-236.6%	-93.6%	-0.8×	-1.15×	-1.98×	1.12×	0.0%	2	-27.45	2	B-
Peer median	—	-1.47×	1.76×	0.55×	-1.69×	-77.1%	88.0%	-13.8%	-8.8%	-78.3%	-97.4%	-57.0%	0.04×	0.08×	0×	3.55×	0.0%	1	-9.17	2	—